新英格兰医学杂志:辉瑞疫苗能够中和巴西变种新冠病毒株
《新英格兰医学杂志》发表最新实验室研究,发现辉瑞-BioNTech 的COVID-19疫苗能够中和具有高度传染的巴西变种新冠病毒株P.1。
研究发现已接种疫苗人士的血液能够中和P.1,而效果大致等同於疫苗中和去年已出现的传染力较低病毒株。
另外,辉瑞(PFE.US)亦表示,相信目前的疫苗很可能可以抵御南非病毒株,但正计划测试第三次加强剂量的疫苗,以及专门为应对变种病毒株而设计的疫苗配方,以便更好地了解免疫反应。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.